ATR and cancer: The profound sensitivity of FEN1-deficient cells to the USP1 inhibitor KSQ-4279 also suggests it might be effective in treating FEN1-mutant cancers or augmenting chemotherapies that induce DNA gap formation, such as ATR and WEE1 inhibitors41.